The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The impact of MRD & genetics on outcomes to time-limited combinations in patients with CLL
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, comments on the importance of considering both measurable residual disease (MRD) status and IgHV mutational status to predict outcomes in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib-venetoclax combinations. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen, Roche, AbbVie, BeiGene, AstraZeneca: Research Funding; Janssen, Roche, AbbVie, BeiGene, AstraZeneca, MSD: Speakers Bureau; Beigene: Other: Travel Support; Janssen, AbbVie, Lilly, AstraZeneca, BeiGene, MSD: Consultancy.
